FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
BiologicsPlatinum Biologics LLC
FDA says Platinum Biologics sells unapproved umbilical cord and exosome biologics without required licenses or approvals.
High risk -
BiologicsInnate Healthcare Institute
FDA warned Arizona clinic Innate Healthcare Institute for selling unapproved umbilical cord stem cells marketed to treat autism.
High risk -
BiologicsBioStem Life Sciences
FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.
High risk -
BiologicsChara Biologics, Inc.
FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.
High risk -
BiologicsEvolutionary Biologics Inc.
FDA warned Evolutionary Biologics that its exosome and umbilical-cord products are unapproved new drugs and unlicensed biologics sold with disease-treatment claims.
High risk -
BiologicsMother Stem Institute, Corp.
FDA warns Mother Stem Institute over unapproved fat-derived SVF 'stem cell' biologic marketed for serious diseases.
High risk -
BiologicsBerkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.
FDA says Berkeley Biologics' viable bone matrix products are unapproved drugs, with donor screening failures tied to tuberculosis infections.
High risk -
BiologicsMiMedx Group, Inc.
FDA cites MiMedx for marketing placental product AXIOFILL without BLA or IND and for CGMP failures.
High risk -
BiologicsSignature Biologics, LLC
FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.
High risk